Daily pill shrank a rare joint tumour in over half of patients
The FDA approved Pimjetmi (pimicotinib) for tenosynovial giant cell tumour after the MANEUVER trial, where tumours shrank substantially in 56% of patients against 3.2% on placebo.
10 November 2026
















